Literature DB >> 21881460

Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series.

Marco Di Nicola, Daniela Tedeschi, Giovanni Martinotti, Ofelia De Vita, Marisa Monetta, Gino Pozzi, Luigi Janiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21881460     DOI： 10.1097/JCP.0b013e31822c29a8

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  3 in total

Review 1.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

2.  The effect of pregabalin on sensorimotor gating in 'low' gating humans and mice.

Authors:  Dean T Acheson; Murray B Stein; Martin P Paulus; Mark A Geyer; Victoria B Risbrough
Journal:  Neuropharmacology       Date:  2012-05-02       Impact factor: 5.250

3.  Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Authors:  Emilio Blanco Tarrio; Rafael Gálvez Mateos; Enric Zamorano Bayarri; Vanessa López Gómez; Maria Pérez Páramo
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.